[
 {
  "trial": "T017",
  "source": "abstract",
  "arms": {
   "Group D (dexamethasone)": {
    "randomized": "99",
    "analysed": null
   },
   "Group KD (ketamine + dexamethasone)": {
    "randomized": "99",
    "analysed": null
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. 297 randomized into three groups of n = 99; Group K (ketamine alone, role 'other') left out. PHQ-9 on postoperative days 1 and 3, VAS at 24 h and PCA consumption are reported only as significance statements (K and KD lower PHQ-9 than D, P < 0.01; KD lower 24-h VAS and PCA consumption, P < 0.05), with no numbers. No adverse events, dates or registration given."
 },
 {
  "trial": "T023",
  "source": "abstract",
  "arms": {
   "Group C": {
    "randomized": null,
    "analysed": "49"
   },
   "Group K": {
    "randomized": null,
    "analysed": "48"
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. 100 randomized 1:1; per-arm randomized numbers not printed. 'analysed' is the number with the primary outcome (QoR-40 on POD1) available, 49 in group C and 48 in group K; no analysed numbers are given for HADS or NRS. HADS (2 days, 3 months), NRS (4, 24, 48 h) and chronic pain are reported only as no difference between groups (p > .15 for each), without numbers. No adverse events, dates or registration given."
 },
 {
  "trial": "T028",
  "source": "abstract",
  "arms": {
   "Control group (normal saline)": {
    "randomized": null,
    "analysed": null
   },
   "Racemic ketamine group": {
    "randomized": null,
    "analysed": null
   },
   "S-ketamine group": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2017-06",
   "end": "2018-06"
  },
  "registration": null,
  "note": "Abstract only. 303 patients randomized into three groups; per-arm numbers not printed. HAMD-17 (3 days, 1 week, 1 month, 3 months) and VAS (1 and 3 days) are described only qualitatively, with no numbers; complication rate said not to differ, no counts. Enrollment dates are from the abstract's Methods ('from June 2017 to June 2018'), not a Results statement."
 },
 {
  "trial": "T044",
  "source": "fulltext",
  "arms": {
   "Group E": {
    "randomized": "60",
    "analysed": "58"
   },
   "Group C": {
    "randomized": "60",
    "analysed": "59"
   }
  },
  "depression": [
   {
    "measure": "EPDS (with diagnostic criteria)",
    "day": 7,
    "form": "count",
    "definition": "PPD diagnosed from the EPDS score and the diagnostic criteria for mental disorders (refs 15, 16); cut-off not stated",
    "location": "Table 3 (PPD, 1 week)",
    "values": {
     "Group E": {
      "events": "2",
      "n": "58"
     },
     "Group C": {
      "events": "9",
      "n": "59"
     }
    }
   },
   {
    "measure": "EPDS (with diagnostic criteria)",
    "day": 42,
    "form": "count",
    "definition": "PPD diagnosed from the EPDS score and the diagnostic criteria for mental disorders (refs 15, 16); cut-off not stated",
    "location": "Table 3 (PPD, 6 weeks)",
    "values": {
     "Group E": {
      "events": "3",
      "n": "58"
     },
     "Group C": {
      "events": "11",
      "n": "59"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3",
    "values": {
     "Group E": {
      "nightmare": "2"
     },
     "Group C": {
      "nightmare": "3"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-06-01",
   "end": "2023-02-28"
  },
  "registration": {
   "number": "ChiCTR2200060387",
   "date": "2022-05-30"
  },
  "note": "Vaginal delivery with labour analgesia; esketamine given after fetal disengagement, so days count from delivery (1 week = 7, 6 weeks = 42). Randomized per arm is from Methods ('A total of 120 samples were designed in this study, for 60 in each group respectively'); 120 enrolled, then 2 excluded in Group E (failed epidural puncture; changed to caesarean) and 1 in Group C (failed epidural puncture), leaving 58 and 59 analysed. Side effects (nightmares, drowsiness, nausea/vomiting) were recorded for 48 h after delivery; drowsiness (1 vs 1) and nausea/vomiting (2 vs 1) are not psychotomimetic categories. Enrollment dates are the trial period stated in Methods (6/1/2022 to 2/28/2023); Results give none. Registration date printed as 5/30/2022."
 },
 {
  "trial": "T060",
  "source": "fulltext",
  "arms": {
   "Morning operation with esketamine": {
    "randomized": null,
    "analysed": "107"
   },
   "Morning operation with saline": {
    "randomized": null,
    "analysed": "105"
   },
   "Afternoon operation with esketamine": {
    "randomized": null,
    "analysed": "106"
   },
   "Afternoon operation with saline": {
    "randomized": null,
    "analysed": "108"
   }
  },
  "depression": [
   {
    "measure": "Hospital Anxiety and Depression Scale (HAD)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 3 (Preoperation)",
    "values": {
     "Morning operation with esketamine": {
      "median": "4",
      "q1": "3",
      "q3": "6",
      "n": "108"
     },
     "Morning operation with saline": {
      "median": "5",
      "q1": "3",
      "q3": "7",
      "n": "108"
     },
     "Afternoon operation with esketamine": {
      "median": "4",
      "q1": "2",
      "q3": "6",
      "n": "108"
     },
     "Afternoon operation with saline": {
      "median": "4",
      "q1": "3",
      "q3": "6",
      "n": "108"
     }
    }
   },
   {
    "measure": "Hospital Anxiety and Depression Scale (HAD)",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3 (Postoperative day 1)",
    "values": {
     "Morning operation with esketamine": {
      "median": "8",
      "q1": "7",
      "q3": "10",
      "n": "107"
     },
     "Morning operation with saline": {
      "median": "8",
      "q1": "7",
      "q3": "10",
      "n": "105"
     },
     "Afternoon operation with esketamine": {
      "median": "8",
      "q1": "6",
      "q3": "10",
      "n": "106"
     },
     "Afternoon operation with saline": {
      "median": "8",
      "q1": "6",
      "q3": "10",
      "n": "108"
     }
    }
   },
   {
    "measure": "Hospital Anxiety and Depression Scale (HAD)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 3 (Postoperative day 3)",
    "values": {
     "Morning operation with esketamine": {
      "median": "8",
      "q1": "6",
      "q3": "10",
      "n": "107"
     },
     "Morning operation with saline": {
      "median": "8",
      "q1": "6",
      "q3": "9",
      "n": "105"
     },
     "Afternoon operation with esketamine": {
      "median": "7",
      "q1": "6",
      "q3": "9",
      "n": "106"
     },
     "Afternoon operation with saline": {
      "median": "8",
      "q1": "6",
      "q3": "10",
      "n": "108"
     }
    }
   },
   {
    "measure": "Hospital Anxiety and Depression Scale (HAD)",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 3 (Postoperative day 7)",
    "values": {
     "Morning operation with esketamine": {
      "median": "7",
      "q1": "6",
      "q3": "9",
      "n": "107"
     },
     "Morning operation with saline": {
      "median": "7",
      "q1": "5",
      "q3": "9",
      "n": "105"
     },
     "Afternoon operation with esketamine": {
      "median": "7",
      "q1": "5",
      "q3": "9",
      "n": "106"
     },
     "Afternoon operation with saline": {
      "median": "7",
      "q1": "5",
      "q3": "9",
      "n": "108"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "postoperative NRS",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 6 (Postoperative day 1)",
    "values": {
     "Morning operation with esketamine": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "107"
     },
     "Morning operation with saline": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "105"
     },
     "Afternoon operation with esketamine": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "106"
     },
     "Afternoon operation with saline": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "108"
     }
    }
   },
   {
    "measure": "postoperative NRS",
    "day": 2,
    "form": "median_iqr",
    "location": "Table 6 (Postoperative day 2)",
    "values": {
     "Morning operation with esketamine": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "107"
     },
     "Morning operation with saline": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "105"
     },
     "Afternoon operation with esketamine": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": "106"
     },
     "Afternoon operation with saline": {
      "median": "3",
      "q1": "1",
      "q3": "4",
      "n": "108"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "emergence",
    "location": "Table 9 (PACU rows)",
    "values": {
     "Morning operation with esketamine": {
      "agitation": "19",
      "dizziness": "33"
     },
     "Morning operation with saline": {
      "agitation": "31",
      "dizziness": "24"
     },
     "Afternoon operation with esketamine": {
      "agitation": "18",
      "dizziness": "21"
     },
     "Afternoon operation with saline": {
      "agitation": "28",
      "dizziness": "18"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 9 (Postoperation rows)",
    "values": {
     "Morning operation with esketamine": {
      "dizziness": "34"
     },
     "Morning operation with saline": {
      "dizziness": "46"
     },
     "Afternoon operation with esketamine": {
      "dizziness": "42"
     },
     "Afternoon operation with saline": {
      "dizziness": "40"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-01-04",
   "end": "2023-03-07"
  },
  "registration": null,
  "note": "2x2 factorial (operation time x esketamine 0.2 mg/kg single dose before induction). Tables abbreviate the arms: AES = Afternoon operation with esketamine, ANS = Afternoon operation with saline, MES = Morning operation with esketamine, MNS = Morning operation with saline. 432 randomized 1:1:1:1; per-arm randomized numbers are not printed (Fig. 1 values not shown; Table 3's preoperative row has n = 108 in every group). Analysed 426: AES 106, ANS 108, MES 107, MNS 105 (Tables 1, 3, 6, 8, 9). 'HAD' scores are copied as the paper reports them (a single HAD score, no subscales). PACU rows of Table 9 coded as emergence (EA = emergence agitation coded as agitation); 'Postoperation' rows as postoperative; intraoperative rows (injection pain, cough, hypotension, hypertension, SpO2 < 95%) hold no psychotomimetic category. Enrollment dates are from Methods ('enrolled between 4 January 2022 and 7 March 2023'). No trial registration number appears in the text (ethics approval WDRY2021-K124, 18 August 2021)."
 },
 {
  "trial": "T070",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": null,
    "analysed": "40"
   },
   "Control group": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "PHQ-9",
    "day": -1,
    "form": "count",
    "definition": "PHQ-9 score ≥ 5",
    "location": "Table 1 (Depression, n (%))",
    "values": {
     "Esketamine group": {
      "events": "2",
      "n": "40"
     },
     "Control group": {
      "events": "0",
      "n": "40"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 1,
    "form": "count",
    "definition": "PHQ-9 score ≥ 5",
    "location": "Table 2 (Depression POD1)",
    "values": {
     "Esketamine group": {
      "events": "1",
      "n": "40"
     },
     "Control group": {
      "events": "3",
      "n": "40"
     }
    }
   },
   {
    "measure": "PHQ-9",
    "day": 2,
    "form": "count",
    "definition": "PHQ-9 score ≥ 5",
    "location": "Table 2 (Depression POD2)",
    "values": {
     "Esketamine group": {
      "events": "1",
      "n": "40"
     },
     "Control group": {
      "events": "6",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS pain score",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2, VAS at T2 (postoperative day 1 morning, 8:00-10:00 a.m.)",
    "values": {
     "Esketamine group": {
      "mean": "2.55",
      "sd": "1.02",
      "n": "40"
     },
     "Control group": {
      "mean": "2.75",
      "sd": "0.75",
      "n": "40"
     }
    }
   },
   {
    "measure": "VAS pain score",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2, VAS at T3 (postoperative day 1 afternoon, 3:00-5:00 p.m.)",
    "values": {
     "Esketamine group": {
      "mean": "2.58",
      "sd": "0.82",
      "n": "40"
     },
     "Control group": {
      "mean": "2.89",
      "sd": "0.65",
      "n": "40"
     }
    }
   },
   {
    "measure": "VAS pain score",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2, VAS at T4 (postoperative day 2 morning)",
    "values": {
     "Esketamine group": {
      "mean": "2.66",
      "sd": "0.68",
      "n": "40"
     },
     "Control group": {
      "mean": "3.14",
      "sd": "0.70",
      "n": "40"
     }
    }
   },
   {
    "measure": "VAS pain score",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2, VAS at T5 (postoperative day 2 afternoon)",
    "values": {
     "Esketamine group": {
      "mean": "2.58",
      "sd": "0.83",
      "n": "40"
     },
     "Control group": {
      "mean": "3.16",
      "sd": "0.67",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2022-07-07",
   "end": "2023-02-20"
  },
  "registration": null,
  "note": "Esketamine was given only in the postoperative PCIA (with sufentanil) for 24 h. Per-arm randomized numbers are not printed (Fig. 1 values not shown); the final analysis (stated as intention-to-treat) included 40 per group, the planned sample size. Depression is reported only as counts of PHQ-9 >= 5, at baseline (Table 1) and on POD1 and POD2 (Table 2, which also gives risk differences 5.0% (-4.5% to 14.5%) and 12.5% (0.4% to 24.6%)). Form of VAS taken as mean_sd from the Statistical analysis (means +/- SD). VAS was measured twice on each postoperative day (T2/T3 on day 1, T4/T5 on day 2) and the hours after surgery are not given, so both readings are entered under each day, told apart by location; VAS at T1 (5 min after extubation) left out. Not entered: 'VAS >3 within 48 h' 11 (27.5%) vs 17 (42.5%), and flurbiprofen and paracetamol rescue use and consumption (non-opioid). Adverse events reported are PONV only (10 vs 10); no psychotomimetic events. Enrollment dates are from Methods ('from July 7, 2022 to Feb 20, 2023'). Registration on ClinicalTrials.gov is stated without a number."
 },
 {
  "trial": "T094",
  "source": "fulltext",
  "arms": {
   "Control group": {
    "randomized": "100",
    "analysed": "100"
   },
   "Esketamine group": {
    "randomized": "100",
    "analysed": "100"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1 (HADS-D score)",
    "values": {
     "Control group": {
      "mean": "8.2",
      "sd": "2.4",
      "n": "100"
     },
     "Esketamine group": {
      "mean": "8.1",
      "sd": "2.5",
      "n": "100"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "overall",
    "location": "Table 4",
    "values": {
     "Control group": {
      "dizziness": "9",
      "dissociation": "3"
     },
     "Esketamine group": {
      "dizziness": "6",
      "dissociation": "15"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2400087795",
   "date": null
  },
  "note": "Postoperative HADS-D (days 1 and 3), VAS at 24 and 48 h, opioid consumption, rescue analgesia rate and non-opioid analgesic use appear only in Fig. 2 (no printed values) and as P values, so only the preoperative HADS-D (collected one day before surgery, Table 1) is entered. Analysed = the tables' n (100 per group); no losses reported. The adverse-event period is not stated (listed among the data collected), so window 'overall'; 'Dizziness or Lightheadedness' coded as dizziness and 'Dissociative Symptoms' as dissociation; nausea or vomiting, headache and sedation are not psychotomimetic categories. No enrollment dates in the text."
 },
 {
  "trial": "T107",
  "source": "fulltext",
  "arms": {
   "Bolus group": {
    "randomized": "168",
    "analysed": "153"
   },
   "Infusion group": {
    "randomized": "168",
    "analysed": "156"
   },
   "Control group": {
    "randomized": "167",
    "analysed": "150"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Baseline EPDS scores)",
    "values": {
     "Bolus group": {
      "median": "5",
      "q1": "2",
      "q3": "7",
      "n": "153"
     },
     "Infusion group": {
      "median": "5",
      "q1": "2",
      "q3": "7",
      "n": "156"
     },
     "Control group": {
      "median": "4.5",
      "q1": "1",
      "q3": "6",
      "n": "150"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "positive PPD screen, EPDS 'more than 10' as printed in Methods (main rows probably EPDS >= 10; see note)",
    "location": "Table 2 (PPD, 1 wk)",
    "values": {
     "Bolus group": {
      "events": "16",
      "n": "147"
     },
     "Infusion group": {
      "events": "17",
      "n": "148"
     },
     "Control group": {
      "events": "22",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "median_iqr",
    "location": "Table 2 (EPDS scores, 1 wk)",
    "values": {
     "Bolus group": {
      "median": "3",
      "q1": "0",
      "q3": "6",
      "n": "147"
     },
     "Infusion group": {
      "median": "4",
      "q1": "1",
      "q3": "6",
      "n": "148"
     },
     "Control group": {
      "median": "3",
      "q1": "0",
      "q3": "6",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 28,
    "form": "count",
    "definition": "positive PPD screen, EPDS 'more than 10' as printed in Methods (main rows probably EPDS >= 10; see note)",
    "location": "Table 2 (PPD, 4 wk)",
    "values": {
     "Bolus group": {
      "events": "18",
      "n": "150"
     },
     "Infusion group": {
      "events": "15",
      "n": "147"
     },
     "Control group": {
      "events": "23",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 28,
    "form": "median_iqr",
    "location": "Table 2 (EPDS scores, 4 wk)",
    "values": {
     "Bolus group": {
      "median": "2",
      "q1": "0",
      "q3": "6",
      "n": "150"
     },
     "Infusion group": {
      "median": "2",
      "q1": "0",
      "q3": "7",
      "n": "147"
     },
     "Control group": {
      "median": "2",
      "q1": "0",
      "q3": "7",
      "n": "145"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "count",
    "definition": "positive PPD screen, EPDS 'more than 10' as printed in Methods (main rows probably EPDS >= 10; see note)",
    "location": "Table 2 (PPD, 6 wk)",
    "values": {
     "Bolus group": {
      "events": "14",
      "n": "153"
     },
     "Infusion group": {
      "events": "18",
      "n": "156"
     },
     "Control group": {
      "events": "29",
      "n": "150"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 42,
    "form": "median_iqr",
    "location": "Table 2 (EPDS scores, 6 wk)",
    "values": {
     "Bolus group": {
      "median": "2",
      "q1": "0",
      "q3": "5",
      "n": "153"
     },
     "Infusion group": {
      "median": "2",
      "q1": "0",
      "q3": "5.75",
      "n": "156"
     },
     "Control group": {
      "median": "3",
      "q1": "0",
      "q3": "7",
      "n": "150"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "NRS at rest",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, Pain Control paragraph (postoperative day 1)",
    "values": {
     "Bolus group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": null
     },
     "Infusion group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": null
     },
     "Control group": {
      "median": "3",
      "q1": "2",
      "q3": "3",
      "n": null
     }
    }
   },
   {
    "measure": "NRS at rest",
    "day": 2,
    "form": "median_iqr",
    "location": "Results, Pain Control paragraph (day 2)",
    "values": {
     "Bolus group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": null
     },
     "Infusion group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": null
     },
     "Control group": {
      "median": "1",
      "q1": "0",
      "q3": "2",
      "n": null
     }
    }
   },
   {
    "measure": "NRS with movement (coughing or walking)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results, Pain Control paragraph (postoperative day 1)",
    "values": {
     "Bolus group": {
      "median": "4",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Infusion group": {
      "median": "4",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group": {
      "median": "4",
      "q1": "3",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "NRS with movement (coughing or walking)",
    "day": 2,
    "form": "median_iqr",
    "location": "Results, Pain Control paragraph (day 2)",
    "values": {
     "Bolus group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": null
     },
     "Infusion group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": null
     },
     "Control group": {
      "median": "3",
      "q1": "3",
      "q3": "4",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3 (During surgery)",
    "values": {
     "Bolus group": {
      "dizziness": "22",
      "nightmare": "6",
      "hallucination": "13",
      "any_ae": "70"
     },
     "Infusion group": {
      "dizziness": "47",
      "nightmare": "9",
      "hallucination": "5",
      "visual": "0",
      "any_ae": "102"
     },
     "Control group": {
      "dizziness": "5",
      "nightmare": "0",
      "hallucination": "0",
      "visual": "0",
      "any_ae": "33"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3 (Within 6 weeks postpartum, In total)",
    "values": {
     "Bolus group": {
      "any_ae": "17"
     },
     "Infusion group": {
      "any_ae": "23"
     },
     "Control group": {
      "any_ae": "20"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-04",
   "end": "2025-04"
  },
  "registration": {
   "number": "ChiCTR2400082919",
   "date": null
  },
  "note": "Randomized 168 bolus, 168 infusion, 167 control; analysed (per protocol, completed 6 weeks) 153, 156, 150. PPD definition: Methods say 'EPDS scores more than 10', but the Statistical analysis calls >= 10 the usual cut-off, prenatal screening excluded EPDS >= 10, and the sensitivity rows at >= 11 differ from the main rows, so the main rows probably use >= 10. Sensitivity counts at EPDS >= 11 and >= 12 (Table 2) and the ITT worst-case results are not entered. Table 2 prints no n for the EPDS median rows; their n is the PPD denominator at the same visit. Pain values come from the text, which lists three values per time without naming the groups; read in the order control, bolus, infusion, the order of every table (the bolus-attempt percentages in the same paragraph, 50.66% vs 54.90% vs 55.12%, fit denominators 150, 153, 156 in that order). The infusion value at rest on day 1 is printed '3 3 (2–3)'. Day-3 NRS left out (outside day 1-2). PCIA total consumption 69.92±12.75 vs 69.25±12.04 vs 68.73±12.31 (control, bolus, infusion; unit not stated; PCIA stopped within 48 h) has no time point and is not entered. Adverse events during surgery: 'Dreamscape' coded as nightmare; the bolus group prints diplopia 1 and nystagmus 1 separately, so its visual count (1 or 2) is not entered, while control and infusion print 0 for both. 'In total' rows coded as any_ae; the 6-week rows hold no psychotomimetic category. Enrollment dates are the trial period in Methods ('between April 2024 and April 2025')."
 },
 {
  "trial": "T116",
  "source": "fulltext",
  "arms": {
   "Esketamine group": {
    "randomized": "68",
    "analysed": "68"
   },
   "Normal saline group": {
    "randomized": "68",
    "analysed": "68"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 2 (Total scores, 2nd day after delivery)",
    "values": {
     "Esketamine group": {
      "mean": "21.10",
      "sd": "2.02",
      "n": "68"
     },
     "Normal saline group": {
      "mean": "23.34",
      "sd": "2.01",
      "n": "68"
     }
    }
   },
   {
    "measure": "PPD incidence",
    "day": 3,
    "form": "count",
    "definition": "PPD; criterion not stated in the paper",
    "location": "Results, 'Comparison of postpartum depression (PPD) incidence' (text)",
    "values": {
     "Esketamine group": {
      "events": "4",
      "n": null
     },
     "Normal saline group": {
      "events": "15",
      "n": null
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 3 (Total scores, 7th day postpartum)",
    "values": {
     "Esketamine group": {
      "mean": "17.86",
      "sd": "2.17",
      "n": "68"
     },
     "Normal saline group": {
      "mean": "20.55",
      "sd": "2.21",
      "n": "68"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "number of compressions of the analgesic pump",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4 (within 24 hours after the operation)",
    "values": {
     "Esketamine group": {
      "mean": "2.57",
      "sd": "0.74",
      "n": "68"
     },
     "Normal saline group": {
      "mean": "4.15",
      "sd": "1.22",
      "n": "68"
     }
    }
   },
   {
    "measure": "number of compressions of the analgesic pump",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4 (within 48 hours after the operation)",
    "values": {
     "Esketamine group": {
      "mean": "3.55",
      "sd": "1.24",
      "n": "68"
     },
     "Normal saline group": {
      "mean": "4.75",
      "sd": "1.33",
      "n": "68"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 6 (rows without 'Postoperative')",
    "values": {
     "Esketamine group": {
      "dizziness": "14",
      "hallucination": "1",
      "dissociation": "1",
      "agitation": "1",
      "visual": "2"
     },
     "Normal saline group": {
      "dizziness": "11",
      "hallucination": "2",
      "dissociation": "3",
      "agitation": "1",
      "visual": "1"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 6 (Postoperative dizziness)",
    "values": {
     "Esketamine group": {
      "dizziness": "3"
     },
     "Normal saline group": {
      "dizziness": "4"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2024-08",
   "end": "2025-08"
  },
  "registration": {
   "number": "ChiCTR2400088992",
   "date": null
  },
  "note": "Single-blind (mothers only). Tables 2 and 3 list the control group first. EPDS entries are the 'Total scores' rows (about 18 to 23), copied as printed. PPD incidence (criterion never defined; EPDS is the only depression instrument named) is given only in the text: day 3, 4 cases (5.88%) vs 15 (22.06%), no denominator printed; days 7 and 14 as percentages only (5.08% vs 22.41%; 5.08% vs 20.69%), which are not k/68 for any whole k, so fewer women were assessed then; day 30 not significant, no numbers; Figure 2 has no printed values. Only day 3 entered, as a count without n. VAS at rest and on movement (4, 12, 24 h) appear only in Figure 4 (no printed values). Analgesic-pump presses (PCIA of butorphanol, flurbiprofen and dexamethasone; Table 4) entered under the source's name as cumulative presses within 24 h (day 1) and 48 h (day 2); time to first press (5.63±0.81 vs 5.79±0.72 h) not entered. Adverse events (Table 6): the rows without 'Postoperative' are the intraoperative events (text: 'During intraoperative adverse reactions'); 'Illusion' coded as hallucination (the text calls them hallucinations), 'Restless and agitated' as agitation, 'Nystagmus' as visual (no diplopia row); 'Disgusting' (nausea), vomiting, hypertension, tremble and hypertonia not coded. Postoperative events were monitored for 24 h. Enrollment dates are the trial period in Methods ('between August 2024 and August 2025')."
 },
 {
  "trial": "T121",
  "source": "library",
  "arms": {
   "Esketamine group": {
    "randomized": "87",
    "analysed": "85"
   },
   "Control group (normal saline; PCIA without esketamine)": {
    "randomized": "87",
    "analysed": "84"
   }
  },
  "depression": [
   {
    "measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)",
    "day": -1,
    "form": "median_iqr",
    "location": "Table 1 (Preoperative EPDS Score)",
    "values": {
     "Esketamine group": {
      "median": "12",
      "q1": "10",
      "q3": "13",
      "n": "85"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "median": "12",
      "q1": "10.8",
      "q3": "14",
      "n": "84"
     }
    }
   },
   {
    "measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)",
    "day": 3,
    "form": "median_iqr",
    "location": "Table 2 (3 days postpartum, EPDS score)",
    "values": {
     "Esketamine group": {
      "median": "9.0",
      "q1": "7.0",
      "q3": "11.0",
      "n": "85"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "median": "10.0",
      "q1": "8.8",
      "q3": "13.0",
      "n": "84"
     }
    }
   },
   {
    "measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)",
    "day": 3,
    "form": "count",
    "definition": "EPDS score ≥ 10",
    "location": "Table 2 (3 days postpartum, PPD risk)",
    "values": {
     "Esketamine group": {
      "events": "37",
      "n": "85"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "events": "53",
      "n": "84"
     }
    }
   },
   {
    "measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)",
    "day": 42,
    "form": "count",
    "definition": "EPDS score ≥ 10",
    "location": "Table 2 (Primary outcome, 6 weeks postpartum PPD risk)",
    "values": {
     "Esketamine group": {
      "events": "16",
      "n": "85"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "events": "33",
      "n": "84"
     }
    }
   },
   {
    "measure": "EPDS (PPD = EPDS >=10; incidence at 6 weeks primary)",
    "day": 42,
    "form": "median_iqr",
    "location": "Table 2 (6 weeks postpartum, EPDS score)",
    "values": {
     "Esketamine group": {
      "median": "6.0",
      "q1": "3.0",
      "q3": "9.0",
      "n": "85"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "median": "7.0",
      "q1": "4.0",
      "q3": "11.3",
      "n": "84"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "Postoperative NRS pain scores at rest and during coughing",
    "day": 1,
    "form": "median_iqr",
    "location": "Results 3.3, text (24 h)",
    "values": {
     "Esketamine group": {
      "median": "3.0",
      "q1": "2.0",
      "q3": "4.0",
      "n": null
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "median": "4.0",
      "q1": "3.0",
      "q3": "5.0",
      "n": null
     }
    }
   },
   {
    "measure": "Cumulative sufentanil consumption (0-12, 12-24, 0-24, 24-48, 0-48 h)",
    "day": 1,
    "form": "mean_sd",
    "location": "Results 3.3, text (0–24 h)",
    "values": {
     "Esketamine group": {
      "mean": "33.5",
      "sd": "9.7",
      "n": null
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "mean": "48.2",
      "sd": "11.8",
      "n": null
     }
    }
   },
   {
    "measure": "Cumulative sufentanil consumption (0-12, 12-24, 0-24, 24-48, 0-48 h)",
    "day": 2,
    "form": "mean_sd",
    "location": "Results 3.3, text (total 48-h consumption, 0–48 h)",
    "values": {
     "Esketamine group": {
      "mean": "59.4",
      "sd": "11.6",
      "n": null
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "mean": "75.5",
      "sd": "14.1",
      "n": null
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3 (Adverse effects during the operation)",
    "values": {
     "Esketamine group": {
      "dizziness": "27",
      "hallucination": "5",
      "nightmare": "2"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "dizziness": "9",
      "hallucination": "0",
      "nightmare": "0"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3 (Adverse effects after surgery)",
    "values": {
     "Esketamine group": {
      "dizziness": "9",
      "hallucination": "2",
      "nightmare": "2"
     },
     "Control group (normal saline; PCIA without esketamine)": {
      "dizziness": "2",
      "hallucination": "0",
      "nightmare": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-10-20",
   "end": "2024-06-16"
  },
  "registration": {
   "number": "ChiCTR2300077191",
   "date": null
  },
  "note": "Women with prenatal EPDS >= 10; esketamine 0.25 mg/kg after cord clamping plus 1.25 mg/kg in the PCIA. Analysed 85 and 84 (2 and 3 withdrew or were lost). Baseline EPDS is the preoperative-interview score, median (Q1, Q3). Exploratory counts at EPDS >= 11, >= 12, >= 13 (days 3 and 42, Table 2) not entered. NRS: the text gives one value pair per time for 'NRS pain scores at rest and during coughing' without saying which, so the 24-h pair is entered under the source's wording rather than either listed measure; the 6-h and 12-h pairs fall outside the day windows, and 48 h is only 'comparable (P > 0.05)'. The text's NRS values are in median [IQR] style although Fig. 2's caption says mean ± SD. Sufentanil (μg): 0–24 h entered as day 1 and the 0–48 h total as day 2; interval values 0–12 h 17.7 ± 6.0 vs 27.6 ± 6.4, 12–24 h 15.8 ± 4.7 vs 20.6 ± 7.0, 24–48 h 25.9 ± 3.3 vs 27.4 ± 4.4 not entered; no n printed for pain. Postoperative adverse events cover the first 48 h. Enrollment dates are the screening period stated in Results ('From 20 October 2023 to 16 June 2024')."
 },
 {
  "trial": "T126",
  "source": "preprint",
  "arms": {
   "Group R (ropivacaine ESP block)": {
    "randomized": "47",
    "analysed": "47"
   },
   "Group K1 (low-dose esketamine)": {
    "randomized": "45",
    "analysed": "45"
   },
   "Group K2 (high-dose esketamine)": {
    "randomized": "47",
    "analysed": "47"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1 (Preoperative HADS-D score)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "mean": "4.6",
      "sd": "1.6",
      "n": "47"
     },
     "Group K1 (low-dose esketamine)": {
      "mean": "4.3",
      "sd": "1.5",
      "n": "45"
     },
     "Group K2 (high-dose esketamine)": {
      "mean": "4.8",
      "sd": "1.4",
      "n": "47"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 0.5,
    "form": "mean_sd",
    "location": "Table 3 (Postoperative HADS-D score, 12 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "mean": "4.1",
      "sd": "1.4",
      "n": "47"
     },
     "Group K1 (low-dose esketamine)": {
      "mean": "3.9",
      "sd": "1.3",
      "n": "45"
     },
     "Group K2 (high-dose esketamine)": {
      "mean": "4.4",
      "sd": "1.5",
      "n": "47"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3 (Postoperative HADS-D score, 24 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "mean": "3.3",
      "sd": "1.2",
      "n": "47"
     },
     "Group K1 (low-dose esketamine)": {
      "mean": "2.9",
      "sd": "1.2",
      "n": "45"
     },
     "Group K2 (high-dose esketamine)": {
      "mean": "3.3",
      "sd": "1.3",
      "n": "47"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 3 (Postoperative HADS-D score, 48 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "mean": "2.9",
      "sd": "1.8",
      "n": "47"
     },
     "Group K1 (low-dose esketamine)": {
      "mean": "2.9",
      "sd": "1.4",
      "n": "45"
     },
     "Group K2 (high-dose esketamine)": {
      "mean": "3.1",
      "sd": "1.5",
      "n": "47"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 3 (Postoperative Dizziness and Dreamy, 12 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "dizziness": "5",
      "nightmare": "8"
     },
     "Group K1 (low-dose esketamine)": {
      "dizziness": "5",
      "nightmare": "8"
     },
     "Group K2 (high-dose esketamine)": {
      "dizziness": "3",
      "nightmare": "14"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3 (Postoperative Dizziness and Dreamy, 24 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "dizziness": "4",
      "nightmare": "4"
     },
     "Group K1 (low-dose esketamine)": {
      "dizziness": "5",
      "nightmare": "5"
     },
     "Group K2 (high-dose esketamine)": {
      "dizziness": "2",
      "nightmare": "4"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 3 (Postoperative Dizziness and Dreamy, 48 h)",
    "values": {
     "Group R (ropivacaine ESP block)": {
      "dizziness": "9",
      "nightmare": "2"
     },
     "Group K1 (low-dose esketamine)": {
      "dizziness": "10",
      "nightmare": "4"
     },
     "Group K2 (high-dose esketamine)": {
      "dizziness": "6",
      "nightmare": "1"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-12-07",
   "end": "2021-04"
  },
  "registration": {
   "number": "ChiCTR2000040659",
   "date": "2020-12-07"
  },
  "note": "Esketamine was given perineurally in the ESP block (mixed with ropivacaine) after induction, not intravenously. Randomized numbers are the abstract's ('139 patients were randomized to group R (n = 47), K1 (n = 45) and K2 (n = 47)'), but Results say 150 recruited, 10 excluded, 'One patient withdrew from group K1. Thus, 139 patients randomized', so K1 may have had 46 randomized; tables use 47/45/47. HADS-D at 12 h coded as day 0.5. Pain: VAS at rest and on coughing (12, 24, 48 h) appear only in Fig. 3 (mean ± SD, no printed values); duration of ESP analgesia (R 784.2 ± 130.9, K1 845.0 ± 134.4, K2 894.5 ± 129.7 min) has no day; remedial analgesia (ketorolac, non-opioid) within 48 h, 31 (66) vs 21 (46.7) vs 9 (19.1); none entered. Adverse events (Table 3) are counts at each of 12, 24 and 48 h, not totals per participant, so they are entered as three postoperative entries told apart by location and should not be summed; 'Dreamy' coded as nightmare; nausea and vomiting not coded. Enrollment dates from Results ('All the cases came from December 7, 2020 to April 2021')."
 }
]